Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

BACKGROUND: Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation. DESIGN AND METHODS: Oral cyclophosphamide, thalidomide, and dexamethasone was...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Morgan, Gareth J., Davies, Faith E., Gregory, Walter M., Bell, Sue E., Szubert, Alexander J., Navarro Coy, Nuria, Cook, Gordon, Feyler, Sylvia, Johnson, Peter R.E., Rudin, Claudius, Drayson, Mark T., Owen, Roger G., Ross, Fiona M., Russell, Nigel H., Jackson, Graham H., Child, J. Anthony
Formato: Artigo
Lenguaje:Inglês
Publicado: Ferrata Storti Foundation 2012
Materias:
Original Articles and Brief Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3291601/
https://ncbi.nlm.nih.gov/pubmed/22058209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.043372
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares